EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Pharmacokinetics and Pharmacodynamics of Faldaprevir Following Multiple Oral Rising Doses in Healthy Volunteers and Subjects with Gilbert's Syndrome

Mabrouk Elgadi, Chan-Loi Yong, Jan Wruck, Curtis L Cooper, Anne-Marie Quinson, Fenglei Huang

Clinical Pharmacology in Drug Development · 2026-01 · 15 (1)

DOI: 10.1002/cpdd.1601 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 22.08.2025. Verfasst von Mabrouk Elgadi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. Hauptthemen laut MEDLINE: Oligopeptides, Thiazoles, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Faldaprevir (FDV) is an investigational NS3/NS4A protease inhibitor for chronic hepatitis C. This study evaluated the safety, tolerability, and pharmacokinetics (PK) of FDV after multiple rising doses in healthy male volunteers and subjects with Gilbert syndrome (GS). In this randomized, double‐blind, placebo‐controlled study, healthy males received once‐daily oral FDV (20, 48, 120 mg [ n = 6 per group], 240 mg [ n = 5]), or placebo ( n = 7). A single dose was given on Day 1, followed by a 72‐h washout and 21 days of dosing from day 4. Separately, 9 GS subjects received open‐label FDV 240 mg daily for 28 days. PK was assessed after the first and last doses; safety was evaluated throughout. FDV showed greater than dose‐proportional increases in exposure (gMean C max,ss : 99–5360 ng/mL; AUC τ ,ss : 1740–50,100 h·ng/mL) and time‐dependent PK with a linearity index >1. Mean t 1/2 was 20–30 h; steady state was reached in 6–7 days with an accumulation ratio of 2.8–3.1. FDV exposure in GS subjects was similar but slightly lower. Total bilirubin increased dose‐dependently, with higher indirect bilirubin in GS subjects. FDV exhibited non‐linear, time‐dependent PK and was generally well tolerated up to 240 mg/day in subjects with or without GS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligopeptidesThiazolesAntiviral AgentsHumansMaleProlineAdultDouble-Blind MethodHealthy VolunteersYoung AdultLeucineAdministration, OralAminoisobutyric AcidsDose-Response Relationship, DrugArea Under CurveMiddle AgedQuinolines

Stichwörter der Autor:innen

CYP 3AFaldaprevirGilbert syndromeHCVNS3/4AOATP 1BPharmacodynamicsPharmacokinetics

Substanzen

ProlinefaldaprevirOligopeptidesLeucineAminoisobutyric AcidsThiazolesAntiviral AgentsQuinolines

Autor:innen und Institutionen

  • Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Zitieren

APA

Elgadi, M., Yong, C. L., Wruck, J., Cooper, C. L., Quinson, A. M., & Huang, F. (2026). Pharmacokinetics and Pharmacodynamics of Faldaprevir Following Multiple Oral Rising Doses in Healthy Volunteers and Subjects with Gilbert's Syndrome. Clinical Pharmacology in Drug Development, 15(1). https://doi.org/10.1002/cpdd.1601

Vancouver

Elgadi M, Yong CL, Wruck J, Cooper CL, Quinson AM, Huang F. Pharmacokinetics and Pharmacodynamics of Faldaprevir Following Multiple Oral Rising Doses in Healthy Volunteers and Subjects with Gilbert's Syndrome. Clinical Pharmacology in Drug Development. 2026;15(1). doi:10.1002/cpdd.1601

BibTeX
@article{Elgadi2026,
  author = {Elgadi, Mabrouk and Yong, Chan-Loi and Wruck, Jan and Cooper, Curtis L and Quinson, Anne-Marie and Huang, Fenglei},
  title = {Pharmacokinetics and Pharmacodynamics of Faldaprevir Following Multiple Oral Rising Doses in Healthy Volunteers and Subjects with Gilbert's Syndrome},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {1},
  doi = {10.1002/cpdd.1601}
}
Kostenlos starten →